Join Growin Stock Community!

Quidelortho corporationQDEL.US Overview

US StockHealthcare
(No presentation for QDEL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

QDEL AI Insights

QDEL Overall Performance

QDEL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

QDEL Recent Performance

-3.64%

Quidelortho corporation

0.05%

Avg of Sector

-0.31%

S&P500

QDEL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

QDEL Key Information

QDEL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

QDEL Profile

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Price of QDEL

QDEL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

QDEL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-16.66
PE Ratio (TTM)
-
Forward PE
6.85
PS Ratio (TTM)
0.57
PB Ratio
0.80
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
46.67%
Net Margin
-41.45%
Revenue Growth (YoY)
-1.89%
Profit Growth (YoY)
-0.96%
3-Year Revenue Growth
-5.83%
3-Year Profit Growth
-10.64%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-16.66
PE Ratio (TTM)
-
Forward PE
6.85
PS Ratio (TTM)
0.57
PB Ratio
0.80
Price-to-FCF
-
Gross Margin
46.67%
Net Margin
-41.45%
Revenue Growth (YoY)
-1.89%
Profit Growth (YoY)
-0.96%
3-Year Revenue Growth
-5.83%
3-Year Profit Growth
-10.64%

  • When is QDEL's latest earnings report released?

    The most recent financial report for Quidelortho corporation (QDEL) covers the period of 2025Q4 and was published on 2025/12/28. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating QDEL's short-term business performance and financial health. For the latest updates on QDEL's earnings releases, visit this page regularly.

  • What is the operating profit of QDEL?

    According to the latest financial report, Quidelortho corporation (QDEL) reported an Operating Profit of -66.3M with an Operating Margin of -9.16% this period, representing a growth of 33.96% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is QDEL's revenue growth?

    In the latest financial report, Quidelortho corporation (QDEL) announced revenue of 723.6M, with a Year-Over-Year growth rate of 2.23%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does QDEL have?

    As of the end of the reporting period, Quidelortho corporation (QDEL) had total debt of 2.8B, with a debt ratio of 0.49. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does QDEL have?

    At the end of the period, Quidelortho corporation (QDEL) held Total Cash and Cash Equivalents of 169.8M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does QDEL go with three margins increasing?

    In the latest report, Quidelortho corporation (QDEL) did not achieve the “three margins increasing” benchmark, with a gross margin of 44.3%%, operating margin of -9.16%%, and net margin of -18.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess QDEL's profit trajectory and future growth potential.

  • Is QDEL's EPS continuing to grow?

    According to the past four quarterly reports, Quidelortho corporation (QDEL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.9. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of QDEL?

    Quidelortho corporation (QDEL)'s Free Cash Flow (FCF) for the period is 86.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 424.85% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of QDEL?

    The latest valuation data shows Quidelortho corporation (QDEL) has a Price-To-Earnings (PE) ratio of -1.42 and a Price/Earnings-To-Growth (PEG) ratio of 0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.